You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Skin cancer

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab

  • Technology appraisal guidance
  • Reference number: TA357
  • Published:  07 October 2015
  • Last updated:  12 September 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The company's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Appraisal Committee members, guideline representatives and NICE project team
  • 7 Sources of evidence considered by the Committee
  • Update information

Update information

September 2017: Reference to a patient access scheme in section 1.1 has been replaced with details of a commercial access agreement. Section 2.3 has been updated with the same information.

ISBN: 978-1-4731-1465-4


Previous page 7 Sources of evidence considered by the Committee
Back to top